Clinical Research

Inclusion Criteria:
 Patients who completed 1 of the 4 Bimatoprost SR Phase 3 studies (192024-091, -092, -093, or -095) and received Bimatoprost SR

Exclusion Criteria: 
-> Female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception during the study

-> Concurrent or anticipated enrollment in another investigational drug or device study during the present study

-> Any condition which would preclude the patient’s ability to comply with study requirements, including completion of the study

-> Patients who were randomized to receive timolol eye drops in the study eye (control group) during the Phase 3 Bimatoprost Studies 192024-091 and -092

Joanne Guzman is our lead ophthalmic research coordinator. She is dedicated to providing patients with access to cutting-edge treatments through clinical trials. She is known for always putting patients first and focusing on how patients benefit from participating in clinical trials. She was an ophthalmic technician prior to joining us in clinical research. Her previous experience in ophthalmology, her attention to detail and genuine empathy has been instrumental in helping our patients understand clinical trials for eye diseases.

Contact Joanne: 202-239-0777 ext 102

Pink Eye (Conjunctivitis) Study

If you do have pink eye, you may be eligible to participate in this research study. Pink eye is an infection of the eye that can cause eye redness, tearing, and eyes feeling sore, gritty, or irritated. Pink eye spreads easily between people and to the other eye of the same person. 

The study will evaluate an investigational drug in the form of eye drops intented to treat pink eye. Both adults and children are eligible to participate.
 
Volunteers who take part in the study will receive all study-related care and study drug at no cost. Volunteers may also be reimbursed for travel expenses. 

No health insurance is required to participate. 

To participate you must: 
-> Be experiencing signs/symptoms of pink eye for no more than the past 4 days.
-> Be interested in taking part in a research study fot up to 13 days. 
-> Be willing to travel to the study center for appointments. 

Are Clinical Trials Safe?

The type of studies we conduct at Vision Consultants and Surgeons are in their last step to obtain FDA-approval for commercial availability and comply with the FDA guidelines for safe research. This means the study medications have already passed extensive testing for safety and efficacy in highly controlled environments. As with any medical treatment, participation in a clinical trial offers benefits and risks. Researches conducting these trials will clearly explain the potencial benefits and risks so you can fell confident about making the best decision. Participants always reserve the right to end their participation at any time, even if the study is not complete. All clinical trials must be approved by an Institutional Review Board (IRB). An IRB is made up of physycians, researchers and members of the local community. Its role is to make sure that the study is ethical and the rights and welfare of participants are protected. This includes ensuring high safety standards and processes are followedm and that risks are minimized and reasonable in relation to potential benefits. The Food and Drug Administration (FDA) also plays an important role in the clinical trials process, ensuring the safety of participants, qualification of researchers and the safety and efficacy of the studies. It’s always best to discuss with your physician whether a clinical trial is right for you.


Why Should I Participate in a Clinical Trial?

Participation in a clinical trial often provides patients access to potential new treatments and to expert health care at leading institutions. By participating in a clinical trial, you play an active role in your health and the health of other by contributing to scientific knowledge that may lead to potential new medical treatments for future patients.